Cubist jumps with Teva settlement
Jon "DRJ" Najarian | email@example.com
The drug maker settled a patent dispute with Teva Pharmaceutical Industries over its Cubicin antibiotic. The agreement delays TEVA's production of the drug as a generic by six months and will make it easier for Cubist to market the drug, its only product. CBST is up 15 percent in the premarket.
SemiLEDs Reports Surprise Loss
The maker of light-emitting diodes reported a loss of $0.03, missing the $0.08 profit forecast. Revenue and guidance also missed the mark, and LEDS is down 23 percent before the bell.
Questcor Sees Revenue Ahead of Consensus
The pharmaceuticals company said paid prescriptions for its Acthar Gel to treat multiple sclerosis more than doubled. The company estimated it had first-quarter sale of $48.6 million, while analysts had expected $33.60 million. QCOR climbs 14 percent before the bell.
(Chart courtesy of tradeMONSTER)